Reduced-Dose Glucocorticoids for GPA & Microscopic Polyangiitis

Conclusion

In patients with severe GPA or MPA, the reduced-dose GC regimen was associated with an increased risk of death, ESKD, progression before remission requiring treatment modification or relapse. This risk was even greater in patients with creatinine levels above 300 μmol/L and in those treated with RTX as induction therapy.

Kaplan-Meier survival curve comparing occurence of primary endpoint at 12 months between patients treated with reduced-dose GC regimen (Yes: orange) and patients treated with standard-dose regimen (No: grey) during the first year of follow-up

Kaplan-Meier survival curve comparing occurence of death or ESKD at 12 months between patients treated with reduced-dose GC regimen (Yes: orange) and patients treated with standard-dose regimen (No: grey) during the first year of follow-up

Kaplan-Meier survival curve comparing occurence of primary endpoint at 12 months between patients treated with reduced-dose GC regimen (Yes: orange) and patients treated with standard-dose regimen (No: grey) during the first year of follow-up, after matching with a propensity score

Disclosures

S. Nagle: None; Y. Nguyen: None; X. Puéchal: None; D. Titeca-Beauport: None; T. Crépin: None; R. Mesbah: None; I. Boudhabhay: None; G. Pugnet: None; J. Woessner: None; R. Outh: None; C. Lebas: None; A. Néel: None; a. Karras: AstraZeneca, 6, GlaxoSmithKlein(GSK), 4, Novartis, 2, Pfizer, 6; E. Hachulla: None; B. Subran: None; P. Kerschen: None; M. Gerfaud-Valentin: None; S. Vinzio: None; T. Goulenok: None; R. Borie: None; S. Humbert: None; Y. Uzunhan: None; S. Melboucy-Belkhir: None; J. Gouin: None; M. Guerry: None; B. Terrier: AstraZeneca, 5, CSL Vifor, 2, GlaxoSmithKlein(GSK), 2.

Nagle S, Nguyen Y, Puéchal X, Titeca-Beauport D, Crépin T, Mesbah R, Boudhabhay I, Pugnet G, Woessner J, Outh R, Lebas C, Néel A, Karras a, Hachulla E, Subran B, Kerschen P, Gerfaud-Valentin M, Vinzio S, Goulenok T, Borie R, Humbert S, Uzunhan Y, Melboucy-Belkhir S, Gouin J, Guerry M, Terrier B. Real-life use of the PEXIVAS reduced-dose glucocorticoid regimen in granulomatosis with polyangiitis and microscopic polyangiitis [abstract]. Arthritis Rheumatol. 2023;75(suppl 9).